FDA Approves Vepdegestrant, First Oral PROTAC Targeting Estrogen Receptor in Breast Cancer 2 years ago AnaIn Clinical TrialsFDA ApprovalsResearch Updates
AI-Driven ECG Technologies Gain Ground as CMS Approves Reimbursement Pathways 2 years ago AnaIn AI & DataBreakthroughsClinical Trials
Inebilizumab Shows Promise in Treating Rare Autoimmune Disease: Phase 3 Trial Results 2 years ago AnaIn AI & DataPharma Industry UpdatesResearch Updates
PDS Biotech Advances HPV-Targeted Immunotherapy with Updated Phase 3 Trial Design and Promising Clinical Data 2 years ago AnaIn Biopharma HighlightsFDA ApprovalsResearch Updates
FDA Approves Breakthrough Gene Therapy for Rare Pediatric Disorder; Advances in Immune Therapeutics and NIH Workshop Spotlight 2 years ago AnaIn Breaking NewsClinical TrialsFDA Approvals
Ocugen’s Retinal Gene Therapy Trials Show Encouraging Progress at NYC Clinical Showcase 2 years ago AnaIn BreakthroughsClinical Trials
AbbVie’s Emraclidine Falls Short in Phase 2 Schizophrenia Trials, But Safety Profile Encourages Future Exploration 2 years ago AnaIn Pharma Industry UpdatesTop Stories
Outlook Therapeutics Cuts Workforce After Wet AMD Trial Misses FDA Benchmark 2 years ago AnaIn People
Novo Nordisk Surges Ahead in Obesity Pill Race as Lilly Stumbles in Pivotal Trial 2 years ago AnaIn BreakthroughsPharma Industry UpdatesTop Stories
Akero Therapeutics Advances Phase 3 Trials for MASH Drug EFX 2 years ago AnaIn Clinical TrialsResearch Updates
Editas Medicine Slashes Workforce to Refocus on Eye Disease Program 2 years ago AnaIn Biopharma HighlightsBreaking NewsBreakthroughsPeople
Strand Therapeutics Raises $153M to Advance mRNA Cancer Therapies 2 years ago AnaIn InvestmentsPeopleResearch Updates
Element Biosciences Secures $277M Series D to Expand Multi-Omics Sequencing 2 years ago AnaIn BreakthroughsDealsFunding RoundsResearch UpdatesTop Stories
Novartis Acquires Kate Therapeutics for $1.1B: A Bold Bet on Neuromuscular Gene Therapy 2 years ago AnaIn Biopharma HighlightsBreaking NewsPharma Industry UpdatesTop Stories
Biotech in 2024: A Year of Quiet IPOs, Fierce Science, and Strategic Shifts 2 years ago AnaIn BreakthroughsClinical TrialsResearch Updates
